Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -46.68% | -6.23% | 9.31% | 3.73% | -25.51% |
| Total Depreciation and Amortization | -13.43% | 96.01% | 8.73% | 5.11% | 3.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.97% | 80.21% | 49.30% | -51.76% | -15.11% |
| Change in Net Operating Assets | 158.40% | -52.89% | -31.37% | -480.66% | -21.52% |
| Cash from Operations | -28.25% | -17.29% | 12.00% | -52.26% | -30.31% |
| Capital Expenditure | 58.26% | -- | -1,327.27% | 3.85% | -180.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 66.96% | -- | -1,327.27% | 3.85% | -180.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,132.14% | -75.00% | -49.16% | -53.36% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 227.31% | -75.00% | 159.34% | -53.36% | -1,067.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.88% | -19.86% | 14.22% | -65.35% | -33.70% |